Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Aesica acquires Merck facility

October 16, 2006 | A version of this story appeared in Volume 84, Issue 42

Aesica Pharmaceuticals has bought the Ponders End pharmaceutical chemicals manufacturing facility of Merck Sharp & Dohme, the U.K. subsidiary of Merck. The transaction also includes a long-term supply agreement that could bring Aesica between $150 million and $300 million in revenues. The facility, which is located in Enfield, North London, will bring Aesica 300 metric tons per year of bulk manufacturing capacity plus the capability to manufacture high-potency compounds. The 74 employees currently working at Ponders End will be transferred to Aesica. Aesica was formed through a management buyout of BASF's Cramlington, England, pharmaceutical chemicals facility in 2004.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.